A Phase 3 Randomized Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

Brief description of study

The purpose of this study is to: 1)Test the safety of the study drugs: pembrolizumab in combination with gemcitabine and cisplatin 2) See how well your body handles pembrolizumab in combination with gemcitabine and cisplatin compared to placebo (a look-alike with no active ingredients) in combination with gemcitabine and cisplatin 3) See if pembrolizumab, gemcitabine and cisplatin slows cancer growth and increases the length of life compared to placebo, gemcitabine and cisplatin.




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.